SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as stakeholders closely watch a high-stakes FDA advisory committee meeting regarding its DMD therapy, which has been intensified by the simultaneous publication of HOPE-3 trial data in The Lancet. Community discussion is heavily polarized, featuring emotional testimonies from patient advocates and intense criticism toward the FDA's handling of the review process and statistical endpoints.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing heavy downward pressure following its earnings report despite a record-breaking performance and raised full-year guidance. The community is actively debating whether this represents a major buying opportunity or a deeper issue with dilution and valuation, while concerns regarding Federal Reserve rate hike expectations and broader macro volatility continue to fuel uncertainty among investors.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is facing significant volatility following mixed results from an FDA advisory committee regarding peptide compounding, which has triggered a 'sell the news' reaction and aggressive short-selling activity. While bulls remain focused on the long-term potential of the peptide market and upcoming earnings, the community is actively debating whether this pullback is a strategic entry point or a sign of deeper regulatory and valuation risks.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense selling pressure as investors brace for the latest interest rate decision and critical earnings reports from major tech companies. Community discourse is sharply divided between those calling for a structural market reversal and others actively playing the high volatility with aggressive scalp strategies and protective hedging.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Singapore.

Seagate Technology Holdings Plc

Seagate Technology is trending as investors weigh strong AI-driven storage demand and robust earnings beats against broader concerns regarding memory sector volatility and cyclicality. The community remains sharply divided between those betting on long-term data infrastructure expansion and skeptics calling for further technical corrections following a period of significant price appreciation.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is experiencing heavy volatility following a Q2 earnings report that beat earnings estimates but missed on revenue, fueling intense community debate over whether the pullback is an overreaction to project timing shifts or a necessary valuation correction for an expensive AI infrastructure play. Despite the sharp decline, bulls are highlighting the company's raised full-year guidance and essential role in the AI data center supply chain as strong reasons to view the drop as an accumulation opportunity.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is experiencing heightened volatility and intense speculative activity as traders position themselves for the upcoming FOMC rate decision. Market participants are aggressively debating whether the Fed will maintain the status quo or surprise the market, with ongoing discussions centered on potential rate hikes, geopolitical risks, and the sustainability of recent AI-driven market momentum.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is experiencing intense market volatility, with community sentiment deeply divided between retail investors aggressively buying the dip based on long-term AI infrastructure growth and skeptics calling for further downside due to macro uncertainty and sector-wide repricing. The current conversation is heavily focused on anticipating the upcoming earnings report and the Federal Reserve's policy decisions, which traders believe will serve as the next major catalysts to force a significant move or a potential short squeeze.

Verra Mobility Corp. engages in the provision of smart mobility technology solutions. It operates through the following segments: Government Solutions, Commercial Services, and Parking Solutions. The Government Solutions segment offers automated safety solutions to state and local governments. The Commercial Services segment provides toll and violation management solutions by partnering with the fleet management and rental car companies. The Parking Solutions segment includes a suite of parking software and hardware solutions. The company was founded in 2004 and is headquartered in Mesa, AZ.

Verra Mobility Corp - Ordinary Shares - Class A

Verra Mobility is trending as traders debate the stock's massive recovery potential following a significant sell-off tied to an Avis contract loss, with community sentiment split between bargain-hunting for a bounce-back and fears over long-term margin erosion. Investors are closely watching for potential new government contracts and leadership updates while the stock remains a popular topic for those analyzing deep value opportunities versus technical short-squeeze scenarios.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing significant volatility as investors debate whether the current semiconductor pullback is a healthy consolidation or a sign that the AI investment cycle is maturing. Community members remain deeply divided, with some actively trading the sharp intraday swings and others debating the impact of geopolitical tensions and rotation into value sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman

Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman PR Newswire SAN...

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS PR Newswire SAN FRANCISCO, June 19, 2026 SAN FRANCISCO, June 19, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD PR Newswire NEW YORK, June 11, 2026 NEW YORK, June 11, 2026...

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS PR Newswire SAN FRANCISCO, May 28, 2026 SAN FRANCISCO, May 28, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD PR Newswire NEW YORK, May 21, 2026 NEW YORK, May 21, 2026...

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On...

AARD Stock Crashes 34% – Here’s Why This Analyst Finds It ‘Hard To Lean Into’ Aardvark At This Stage

Equity

Following a clinical hold on its lead drug candidate, multiple brokerages downgraded and cut AARD’s price target.

FDA Halts Aardvark Therapeutics Rare Disease Study

FDA places full clinical hold on Aardvark's ARD-101 studies as the company reviews Phase 3 safety and efficacy data.read more...

AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program

Aardvark Therapeutics said the FDA’s full clinical hold applies to the ongoing late-stage HERO trial for hyperphagia in PWS patients and the associated open-label extension (OLE) study.


Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Aardvark Therapeutics Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$5.94
Prev Close	$6.42
Open	$6.67
Dividend Yield	0.00%
50-Day Moving Average	$4.91
Beta	1.83
Avg. Volume	220,549.21
PE Ratio	-2.00

52-Week High	$17.94
52-Week Low	$3.35
Market Capitalization	$140.5M
EPS (Annual)	-$2.64
Price to Book	1.61
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

AARDAardvark Therapeutics Inc

Latest AARD News